Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Pramlintide cycle length: what human studies ran

Approved, no longer marketedAHuman trial evidence
Short answer: Pramlintide has no "cycle". As an approved drug it is used as its label and a prescriber direct.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Pramlintide combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Pramlintide cycle length?
No cycle is defined. Pramlintide is an approved drug whose label describes treatment under a prescriber's care; the label, not a cycle, governs duration.
What is the longest human study of Pramlintide?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Pramlintide dosing reference Full research page

References

  1. SYMLIN (pramlintide acetate) injection, prescribing information (SymlinPen; DailyMed, label revised 12/2019) FDA label (DailyMed). 2019
  2. Drugs@FDA (openFDA) application record NDA 021332, SYMLIN U.S. FDA. 2026
  3. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes Diabetes Care. 2002
  4. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity Diabetes Care. 2008
  5. World Anti-Doping Agency Prohibited List 2026 (online version) WADA. 2026
  6. PubChem compound record for pramlintide PubChem. 2026